CoChat

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Fakih, Marwan G, Kopetz, Scott, Kuboki, Yasutoshi, Kim, Tae Won, Munster, Pamela N, Krauss, John C, Falchook, Gerald S, Han, Sae-Won, Heinemann, Volker, Muro, Kei, Strickler, John H, Hong, David S, Denlinger, Crystal S, Girotto, Gustavo, Lee, Myung-Ah, Henary, Haby, Tran, Qui, Park, Joseph K, Ngarmchamnanrith, Gataree, Prenen, Hans, Price, Timothy J · 2022 · The Lancet Oncology

The DOI matches its Crossref record; 16 of the 23 references it cites were found in a registry or an index, and 7 are not checked yet.

Abstract

Background Sotorasib, a specific, irreversible KRAS G12C protein inhibitor, has shown monotherapy clinical activity in KRAS G12C -mutated solid tumours, including colorectal cancer, in the CodeBreaK100 phase 1 trial. We aimed to investigate the activity and safety of sotorasib in phase 2 of the trial. Methods In this single-arm, phase 2 trial, adult patients with KRAS G12C -mutated advanced solid tumours were enrolled, from 59 medical centres in 11 countries, if they were aged 18 years or older, had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, and had an Eastern Cooperative Oncology Group performance status of 1 or lower. Only data for patients with colorectal cancer, enrolled at 33 medical centres in nine countries, are presented from this basket trial. To be enrolled, the patients had to have progressed after receiving fluoropyrimidine, oxaliplatin, and irinotecan treatment. These patients were administered 960 mg sotorasib orally once per day until disease progression, development of unacceptable side-effects, withdrawal of consent, or death. The primary endpoint was objective response (complete or partial response) as assessed by blinded independent central review. Response was evaluated in patients who received at least one dose of sotorasib and had at least one measurable lesion at baseline; safety was evaluated in patients who received at least one dose of sotorasib. This analysis is a prespecified…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00605-7

Cites

16 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

16 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Hong, 2021, Proc Am Soc Clin Oncol, 39

Cited by

See all 335

Metadata

Authors
Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., Strickler, J. H., Hong, D. S., Denlinger, C. S., Girotto, G., Lee, M.-A., Henary, H., Tran, Q., Park, J. K., Ngarmchamnanrith, G., Prenen, H., & Price, T. J.
Affiliations
  • City Of Hope National Medical Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • National Cancer Center Hospital East (JP)
  • Asan Medical Center (KR)
  • University of California, San Francisco (US)
  • U-M Rogel Cancer Center (US)
  • HealthONE (US)
  • Seoul National University Hospital (KR)
  • LMU Klinikum (DE)
  • Aichi Cancer Center Hospital (JP)
  • Duke Medical Center (US)
  • Fox Chase Cancer Center (US)
  • Hospital de Base (BR)
  • The Catholic University of Korea Seoul St. Mary's Hospital (KR)
  • Amgen (United States) (US)
  • Antwerp University Hospital (BE)
  • Queen Elizabeth Hospital (AU)
Corresponding author
Fakih, Marwan G
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2022-01
Volume
23
Issue
1
Pages
115-124
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4200037575
Cited by
320
References
23
Citations by year
2026: 42 · 2025: 55 · 2024: 83 · 2023: 89 · 2022: 51
FWCI
20.53
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
sotorasib, KRAS G12C mutation, colorectal cancer, KRAS inhibitors, objective response rate, treatment-related adverse events, diarrhea, acute kidney injury, back pain, basket trials, monotherapy
MeSH terms
Adult, Aged, Female, Humans, Male, Middle Aged, Mutation, Piperazines, Pyridines, Pyrimidines, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00605-7
The paper
Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., Strickler, J. H., Hong, D. S., Denlinger, C. S., Girotto, G., Lee, M.-A., Henary, H., Tran, Q., Park, J. K., Ngarmchamnanrith, G., . . . Price, T. J. (2022). Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00605-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.